Syd Labs D-荧光素钾盐可以用水溶解吗？

Syd Labs D-荧光素钾盐可以用水溶解吗？这些文献带你了解

Syd Labs D-荧光素钾盐（D-Luciferin Potassium Salt,CAS号:115144-35-9）可以用水溶解吗？Syd Labs D-荧光素钾盐（D-Luciferin Potassium Salt，货号MB000102-R70170或MB102-R70170），是一款被用于动物体内实验、在国外已经受到检验的产品。这间接说明，Syd Labs D-荧光素钾盐（D-Luciferin Potassium Salt）在质量和价格上都很有竞争优势。Syd Labs D-荧光素钾盐（D-Luciferin Potassium Salt）目前已经登陆中国市场，有意进入中国高校的动物实验中心和实验室。

Syd Labs D-荧光素钾盐（D-Luciferin Potassium Salt，货号：MB000102-R70170或MB102-R70170），凭借其卓越性能，已获得欧美多所大学core facilities的广泛好评。作为美国Syd Labs公司的特色产品之一，Syd Labs D-荧光素钾盐（D-Luciferin Potassium Salt）不仅在众多欧美实验室中被用于动物体内实验，而且被许多国际知名学术期刊大量收录，这充分说明Syd Labs D-荧光素钾盐（D-Luciferin Potassium Salt）在科研领域具有高度的实用价值。

Syd Labs D-荧光素钾盐（D-Luciferin Potassium Salt）作为一项科研领域的重要实验材料之一，被下方三篇文献引用：

42.

PRDX-1 supports the survival and antitumor activity of primary and CAR-modified NK cells under oxidative stress

Marta Klopotowska,et al.

Cancer Immunol Res. 2022 Feb;10(2):228-244. doi: 10.1158/2326-6066.CIR-20-1023. Epub 2021 Dec 1.

Ten days after tumor cell inoculation, mice received 5.0 × 106 of either NK-92MI-mRFP-pSLIEW-luc cells or NK-92MI-PRDX1-mRFP-pSLIEW-luc cells intratumorally. Immediately following the injection of NK-92MI cells, bioluminescence imaging (BLI) was performed with 100 μL of d-luciferin (Syd Labs; 150 mg luciferin/kg body weight). The NK cell imaging was performed using the IVIS Imaging System (Xenogen). Images were analyzed with the Living Image 4.3 software package (Caliper Life Science). To quantify the BLI signal of NK-92MI cells, the regions of interest were drawn on the tumor region, and the results were used to generate the BLI data presented as total flux (photons/second).

43.

A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis

Lucía Zhu,et al.

EMBO Mol Med. 2022 Mar 7;14(3):e14552. doi: 10.15252/emmm.202114552. Epub 2022 Feb 17.

All animal experiments were performed in accordance with a protocol approved by the CNIO (IACUC.030-2015), Instituto de Salud Carlos III (CBA35_2015-v2), and Comunidad de Madrid Institutional Animal Care and Use Committee (PROEX250/15 and PROEX135/19).Females athymic nu/nu (Harlan) or equal proportions of C57BL/6 males and females mice (for the B16/F10-BrM model) 4–10 weeks of age were used. Housing and husbandry conditions are in accredited by AAALAC. Mice are SPF with microbiological and environmental parameters constantly monitored. Brain colonization assays were performed by injecting 100 ll PBS into the left ventricle containing 100,000 or 40,000 cancer cells or 2 ll RPMI1640 intracranially (the right frontal cortex, approximately 1.5 mm lateral and 1 mm caudal flow bregma, and to a depth of 1 mm) containing 100,000 cancer cells by using a gas-tight Hamilton syringe and a stereotactic apparatus. Brain colonization was analyzed in vivo and ex vivo by BLI.Anesthetized mice (isoflurane) were injected retro-orbitally with Dluciferin (150 mg/kg; Syd Labs) and imaged with an IVIS machine(Perkin Elmer). Bioluminescence analysis was performed using Living Image software, version 4.5. Brain tumor resection was performed by adapting previously described procedures (Morrissyet al, 2016). In brief, after exposing the skull, a craniotomy is performed surrounding the tumor area, which is visualized by GFP,using an excitation light source at 460–495 nm (FS/ULS-02 B2, BLS Ltd) and goggles carrying emission filters (FHS/EF-3GY1, BLS Ltd).The skull and the dura are lifted with micro-dissecting forceps, and the bulk of the tumor is then removed using a microcurette guided by GFP. When hemostasis is obtained, the surgical wound is sutured using interrupted stitching with absorbable sutures. Animals receive meloxicam at 5 mg/kg once per day during 72 h and dexamethasone at 13 mg/kg once per day during 48 h to contain brain edema.DEBIO-0932 was administered by oral gavage (160 mg/kg) for 3 weeks, daily during the first week and once every 48 h during the two following weeks, starting 7 or 14 days after intracardiac inoculation of H2030-BrM for preventive or interventive therapy, respectively. For preventive therapy of relapse after neurosurgery, DEBIO0932 was administered by oral gavage (160 mg/kg) for 5–6 weeks,starting 3 days after neurosurgery. Treatment was given in anindividualized regimen according to clinical symptoms of toxicity,including mouse weight, diarrhea, and activity of the animal. For combination therapy of DEBIO-0932 with autophagy inhibitors,DEBIO-0932 was administered following the interventive setting, and chlorpromazine at 5 mg/kg or trifluoperazine at 10 mg/kg was administered daily intraperitoneally for 3 weeks, starting at 14 days after intracardiac inoculation of H2030-BrM cells. For interventive therapy of DEBIO-0932 (160 mg/kg) in B16/F10-BrM tumors, treatment was given daily for 10 days starting at 3 days after intracranial inoculation of cancer cells.

44.

Limited variation between SARS-CoV-2-infected individuals in domain specificity and relative potency of the antibody response against the spike glycoprotein

Hanora A Van Ert,et al.

Microbiol Spectr. 2022 Feb 23;10(1):e0267621. doi: 10.1128/spectrum.02676-21. Epub 2022 Jan

For neutralization assays, 2-fold serial dilutions of the serum samples were prepared in DMEM–5% FCS, ranging between 1:40 and 1:2,560. Viruses were added to the diluted serum at a concentration calculated to yield between 100,000 and 200,000 relative light units (RLUs) of luciferase activity per well. These values were determined to be within the linear range of virus input versus luciferase activity measured. Vero-E6 target cells were seeded the day before infection in 96-well white opaque flat-bottomed plates (1.5 × 104 cells per well). The virus-serum or virus-plasma mixture was incubated for 1 h at 37°C and added to the wells. Six replicate wells were used for each condition. Samples were then incubated for 24 h at 37°C, after which the media were removed and 35 μl of passive lysis buffer (Promega) was added to each well. Luciferase activity was recorded as a measure of viral infection, as previously described (24). Briefly, 100 μl of luciferin buffer containing 15 mM MgSO4, 15 mM KPO4 (pH 7.8), 1 mM ATP, and 1 mM dithiothreitol was added to each well, followed by 50 μl of 1 mM d-luciferin potassium salt (Syd Laboratories). Luminescence was detected using a Synergy H1 Hybrid reader (BioTek Instruments).